Microarray Analysis of the Molecular Mechanism...
Transcript of Microarray Analysis of the Molecular Mechanism...
Research ArticleMicroarray Analysis of the Molecular Mechanism Involved inParkinson’s Disease
Cheng Tan, Xiaoyang Liu, and Jiajun Chen
Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China
Correspondence should be addressed to Jiajun Chen; [email protected]
Received 24 May 2017; Revised 21 August 2017; Accepted 18 October 2017; Published 1 March 2018
Academic Editor: Amnon Sintov
Copyright © 2018 Cheng Tan et al. )is is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. )is study aimed to investigate the underlying molecular mechanisms of Parkinson’s disease (PD) by bioinformatics.Methods. Using the microarray dataset GSE72267 from the Gene Expression Omnibus database, which included 40 blood samplesfrom PD patients and 19 matched controls, differentially expressed genes (DEGs) were identified after data preprocessing,followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses.Protein-protein interaction (PPI) network, microRNA- (miRNA-) target regulatory network, and transcription factor- (TF-)target regulatory networks were constructed. Results. Of 819 DEGs obtained, 359 were upregulated and 460 were downregulated.Two GO terms, “rRNA processing” and “cytoplasm,” and two KEGG pathways, “metabolic pathways” and “TNF signalingpathway,” played roles in PD development. Intercellular adhesion molecule 1 (ICAM1) was the hub node in the PPI network; hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b participated in PD pathogenesis. Six TFs, including zinc finger and BTB domain-containing 7A, ovo-like transcriptional repressor 1, GATA-binding protein 3, transcription factor dp-1, SMAD family member 1,and quiescin sulfhydryl oxidase 1, were related to PD. Conclusions. “rRNA processing,” “cytoplasm,” “metabolic pathways,” and“TNF signaling pathway” were key pathways involved in PD. ICAM1, hsa-miR-7-5p, hsa-miR-433-3p, hsa-miR-133b, and theabovementioned six TFs might play important roles in PD development.
1. Introduction
Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases [1].)e age at PD onset isapproximately 55 years, and the incidence in the populationaged> 65 years is approximately 1% [1–3]. PDmainly occursbecause of the death of dopaminergic neurons in the sub-stantia nigra [4]. Patients with PD present with symptomssuch as bradykinesia, resting tremor, rigidity, and posturalinstability [5]. )e current therapy for PD is targeted at itssymptoms rather than at dopaminergic neuron degeneration[1]. )e diagnosis of PD at the early stage is challenging, andsuccessfully managing PD is difficult at its later stages [4]. Todate, the cause of PD remains unknown; however, it appearsto involve the intricate interplay of environmental andgenetic factors [1, 4].
Much effort has been spent in investigating PD patho-genesis, and the misfolding, aggregation, and aberrance ofproteins are considered to be some of the main causes
[1, 4, 5]. Some key genes such as hydrogen sulfide, chro-mobox 5 (CBX5), and transcription factor 3 (TCF3) arerelated to PD [6, 7]. Several pathways have also beenidentified to be related to PD. Activation of the proteinkinase B (Akt)/glycogen synthase kinase 3 beta/(GSK3β)pathway by urate reportedly protects dopaminergic neuronsin a rat model of PD [8]. In addition, the E2-related factor 2(Nrf2)/antioxidant response element pathway reportedlycounteracts mitochondrial dysfunction, which is a prom-inent PD feature [9]. )e ubiquitin, lipid, nigrostriatal,autophagy-lysosome, and endosomal pathways are alsoinvolved in PD [10–15]. Furthermore, a recent study revealedseveral microRNAs (miRNAs) associated with PD; miR-205suppresses LRRK2 expression andmiR-205 expression levelsin the brains of patients with PD decreases [16]. Further-more, miR-34b and miR-34c are downregulated in thebrains of patients with PD, which is related to the reductionin the expression ofDJ-1 and PARKIN [17], andmiR-133 andmiR-7 are also associated with PD [18–20]. Numerous
HindawiParkinson’s DiseaseVolume 2018, Article ID 1590465, 12 pageshttps://doi.org/10.1155/2018/1590465
reports that have described the roles of transcription factors(TFs) in PD have also been published. �e TF paired-likehomeodomain 3 has roles in developing and maintainingdopaminergic neurons [21, 22], and engrailed l, which isdownregulated in the rat models, plays a role in the apo-ptosis of dopaminergic neurons and the symptoms of PD[23]. Moreover, Nrf2, nuclear factor kappa B (NF-κB),GATA2, and PHD �nger protein 10 are TFs involved in PD[24–27]. However, understanding the key mechanismsunderlying the development of PD remains unclear.
In a previous study, the microarray dataset GSE72267generated by Calligaris et al. [7] was used to identify keydi�erentially expressed genes (DEGs) such as CBX5, TCF3,
dedicator of cytokinesis 10, and mannosidase alpha class 1Cin the blood of patients with PD compared with those ofhealthy controls. Moreover, crucial pathways related tochromatin remodeling and methylation were revealed. Inthe current study, we downloaded this microarray dataset tocomprehensively analyze DEGs in patients with PD com-pared with those in matched controls by bioinformaticsapproaches and to describe their functional annotations.Compared with the previous analysis conducted by Calli-garis et al. [7], we performed additional analyses, includingthose for the protein-protein interaction (PPI), miRNA-target regulatory, and TF-target regulatory networks, tofurther elucidate the key mechanisms underlying PD. Our
HC0
1H
C02
HC0
3H
C04
HC0
5H
C06
HC0
7H
C08
HC0
9H
C10
HC1
1H
C12
HC1
3H
C14
HC1
5H
C16
HC1
7H
C18
HC1
9PD
01PD
02PD
03PD
04PD
05PD
06PD
07PD
08PD
09PD
10PD
11PD
12PD
13PD
14PD
15PD
16PD
17PD
18PD
19PD
20PD
21PD
22PD
23PD
24PD
25PD
26PD
27PD
28PD
29PD
30PD
31PD
32PD
33PD
34PD
35PD
36PD
37PD
38PD
39PD
40
2
4
6
8
10
12
14
Data normalization
Gen
e exp
ress
ion
Figure 1: Boxplots for normalized gene expression data. Red represents the blood samples of patients with Parkinson’s disease, and whiterepresents the healthy matched control samples.
KEGG pathway CC
MFBP
0
5
10
15
20
25
30
35
40
45
50
hsa0
0562
: ino
sitol
pho
shat
e met
abol
ism
hsa0
1100
: met
abol
ic p
athw
ays
hsa0
3015
: mRN
A su
rvei
llanc
e pat
hway
hsa0
3018
: RN
A d
egra
datio
n
GO
:003
2355
~res
pons
e to
estr
adio
l
GO
:000
6364
~rRN
A p
roce
ssin
g
GO
:009
0102
~coc
hlea
dev
elopm
ent
GO
:000
6351
~tra
nsci
ptio
n, D
NA
tem
plat
e
GO
:000
6417
~reg
ulat
ion
of tr
ansla
tion
GO
:000
1518
~vol
tage
-gat
ed so
dium
chan
nel c
ompl
ex
GO
:000
178~
exos
ome (
RNas
e com
plex
)
GO
:000
5261
~cat
ion
chan
nel a
ctiv
ity
GO
:000
3723
~RN
A b
indi
ng
GO
:000
1078
~tra
nscr
iptio
nal r
epre
ssor
activ
ity, e
tc.
Gen
e cou
nts
(a)
0
20
40
60
80
100
120
140
160
180
hsa0
5416
: vira
l myo
card
itis
hsa0
5164
: infl
uenz
a Ahs
a053
32: g
ra�-
vers
us-h
ost d
iseas
ehs
a046
68: T
NF
signa
ling
path
way
hsa0
5032
: mor
phin
e add
ictio
nG
O:0
0603
33~i
nter
fero
n ga
mm
a-m
edia
ted
signa
ling
path
way
GO
:007
0373
~neg
ativ
e reg
ulat
ion
of E
RK1
and
ERK2
casc
ades
GO
:003
4142
~tol
l-lik
e rec
epto
r 4 si
gnal
ing
path
way
GO
:003
2088
~neg
ativ
e reg
ulat
ion
of N
F-ka
ppaB
tran
scrip
tion,
etc.
GO
:003
5335
~pep
tidyl
-tyro
sine d
epho
spho
rylat
ion
GO
:004
2612
~MH
C cla
ss I
prot
ein
com
plex
GO
:001
2507
~ER
to G
olgi
tran
spor
t ves
icle
mem
bran
eG
O:0
0099
86~c
ell s
urfa
ceG
O:0
0057
37~c
ytop
lasm
GO
:007
1556
~int
egra
l com
pone
nt o
f lum
enal
side
, etc
.G
O:0
0426
05~p
eptid
e ant
igen
bin
ding
GO
:001
9001
~gua
nyl n
ucle
otid
e bin
ding
GO
:000
4725
~pro
tein
tyro
sine p
hosp
hata
se ac
tivity
GO
:005
0840
~ext
race
llula
r mat
rix b
indi
ngG
O:0
0517
8~in
tegr
in b
indi
ng
KEGG pathway CC
MFBP
Gen
e cou
nts
(b)
Figure 2: Functional enrichment analyses of di�erentially expressed genes (DEGs). (a) Gene Ontology (GO) terms and the Kyoto En-cyclopedia of Genes and Genomes (KEGG) pathways of upregulated DEGs and (b) GO terms and KEGG pathways of downregulated DEGs.�e numbers on the x-axis were the ID of pathways or GO terms. �e numbers on the y-axis were gene counts.
2 Parkinson’s Disease
results may provide useful data for diagnosing andtreating PD.
2. Materials and Methods
2.1. A�ymetrix Microarray Data. Gene expression pro�ledata GSE72267 was extracted from the Gene ExpressionOmnibus database (https://www.ncbi.nlm.nih.gov/geo/) [28].�e GSE72267 dataset was deposited by Calligaris et al. [7],
including blood samples from 40 PD patients and 19 healthymatched controls andwas based on the platform of the GPL571(HG-U133A-2) A�ymetrix Human Genome U133A 2.0 Array(A�ymetrix Inc., Santa Clara, California, USA). �is datasetwas downloaded and analyzed on October 2016.
2.2.DataPreprocessing andDEGScreening. �e downloadeddata in CEL �les were preprocessed using the A�y package
MTMR10FNDC3A
MCCC2
MLANA
CHATTPD52ACAA2
NTRK3
ABI2
ITGB4
HPSETRPC1
MAST4EZH1
EPOR
AIMP2
TNFRSF25
ABCC6
MCF2L CDYL
SLA ETFA
ITGB1BP2
ETFDH
FSTL1
SPTBN1CBLBSYN3 PDP1CALR
SETBP1ANXA4SLC25A20
TSPO2
SPRY2APPBP2
HLA–C
ACTL6B
SLC27A2
THPO
AVIL
IL22RA1
NPAS3
SFTPBNPM3
CACYBP
HLA–DQB1
SH3BP5BRD3
CD83 IL9R
SYNE1NMT2
KIDINS220
HADHBALDH6A1
CROT
KCNMB4
PSPN
SCLY
UFSP2
SCNN1AKCND3
CNNM2ASXL1
DMXL2PRDX2ITGB3
MECOM HSPA1L
RPS6KA6
INPP5B
PIK3C2BCYLDEHMT2
KCNMA1AREG
GNAO1
VDAC2
STK38
MAP2K7
ICAM1CA2
FGF7TRIP12
APLP2
CREMBMP6SSH1
FRKACTN2GDF9
AASDHPPT
SMAD1
DTNB
NFKBIA
RUFY1
LRP1HEATR6
FLT3DDX6DUSP2
CADM1 HIST1H2BN
DUSP6
IRAK3
TAL1
SYN1
WDR1ITGA2B
FGFR3
KAT6BSOCS1TLX2AGPAT1 MLLT10
FKBP5
XAF1 SCN11A
LTK
SCN3A
SP100 PTPN2
SBNO1 H2AFY
PHC3
RAP2A
ITSN2
MAPK4
CASP8TIMP1
MED6
IL1RN
AKAP13
MMP25
INPP4A
PDE3A
HLF
ID3
KLC2
FLT3LG KIF5B
KDELR1
CD86
ACSBG1
LBP
GPSM2
MSR1 GNAI2ADORA2B
GHRHR
APOC1CD163
LDLR
RGS5
CRHR2SORT1
GP2
COG2
ICAM4
MTMR1ZBTB38
SYNGR1
PTN
CETP
SLK
COG5
ADCK3
ECHDC3
GFRA2
BAALC
KYNU
IVNS1ABPAGMAT
PARP11
COL5A1
SLC12A3
OLFML2B
VPREB3
BANK1
PLOD1QSOX1
DLGAP4FGFR1OP
PAIP1SCN8A
COX16
NRD1TSN
URB1
MYO6
TSC22D3
MYL12A
RNF114ZMYND11
SUV39H2
TRPC4
SYNCRIP
ENC1 ARIH2CAPN6
TRPM3
COL16A1CD151
LETM1
RNF115
KLF9
HPCAL4
CGGBP1
SMPD1
CTBP2 SEC23IP
CORO2BSART3 SSX2IP
TRPC5
AHCYL1
HGD
PSMD1
ACVR1B
SAP30
CBX4
MID1
TNFAIP3
CBX5PCGF2
MYO10
AKTIP
ZCWPW1
KIF18A
DIAPH2
HOMER1
KIF17
CMKLR1
PEF1
MLLT11
NINL
LDLRAD4
KLHL22
ASS1
PDCD6
CSH1
FERMT2NUDT6CD160HLA–GMR1
KCNG1BPNT1
TPO
TRPM6
CAMK1G
LARGEFBLN1
COL6A1
KLHL3
PHF8
SLC11A2
BMX
FAM110B
CTDSPL
PCDH17
VCAN
ALKBH1
CFDP1 STAP1
HFEIFNW1
KCNK1ZNF500
STS
SATB2 CD96
EFCAB2
SYT11
HGSNAT
SLC7A7 MFSD9ALG8DOCK10IL18R1DYNC2LI1 CRYBA1
NRP2STX5
SEMA3C
CTSB
P2RX1GORASP2EEA1
RORBHBA1
PTGER3 MCHR1CCR6
EDN3
TRAF3IP2ETV1
CCR4LAP3WIPF2
PGPEP1
GOSR1FPR3BNIP3
IL27RA MYCBP2CST7
NPY1R
CCZ1
ECE2GABRA5
CYP1B1
ALDH2
ADH6
DMWD
AKR1C2USP33
CYB5A
ASMT
GPR18
CD248RAB9A
PCBP3ABHD6
PROX1
PREPL
OR2C1CPM
POLE3
EIF3A
ARRB2ST14
CHM
GABARAPL2
BFSP1SLC6A14KCTD14PCNXIL18RAPOSBPL1A
TBC1D8
MAN1C1SERPINB3
CES1
HMGXB4
GPR88
GPR135PTPRM
TSPAN13
PTPRK
TSPAN15
PPFIBP1
TSPAN31
MSI1
FOXD1
MTRF1L
DPYSL4
PAPOLG
FAM63B
B3GALNT1
WDR82B3GALT2
GAL3ST4
GALNT10
MCMBPDHODH
RBM15B
PPP1R8
SERBP1
RRP7A
DNASE2B
GRSF1 CA12
GLYR1ACOT9
AMFR
TMPRSS2
BAG5
EXOSC2
NOP14
TTBK2
CPVL
KPNA6
ATP1B3
SQRDL
NEK1
EFHD2
RPS14 DHX35
RTCATNPO1
SMG7
GLTSCR2
RPS2
FLVCR2
DDX27
MRPS15
RAD51D
OASL
AURKAGATA3
MBD3CCNB1DSP
ISG20L2TNPO3
RRAGA CIB2RSRC1
HOXC4 FTO
PAICS
NXF1
USP39
PLSCR1
PSMD11
TPI1
MCM4ATM
CHAF1A
RPS28
PA2G4
SSRP1
RIPK2BOLA2
CCNA2 TNIP3
BRCA2 PGK1
PFASEEF2
CYP2C9
EEF1D PUS1
ZBTB7A
NME8
PBX2
HIC1GREB1L SRSF7 SON
HIC2 ZNF362
MAFG
U2AF1CBS
HNRNPMTLN2
GRIN2C
ING1
IPO7
SHPKARIH1
ZNF764
TRA2A
EPB41L4A
SPTLC2
MANBA
BTG1
HERPUD1TGFBI
RBM8ALSM5
REEP5
CD40SYNJ2
TCF3NCOA1
HOXB2PLK3VCAM1
F2R
SOS2SP2
PML
NPM1PTEN
CDC14A
NOTCH2CEBPD
XIAP
ARID4B
PKNOX1
ESRRA GTF2A1
TNK2
NPAS2
DUSP3
SLC1A6CASP2
PPP2R1B
PRKDC
CDK3
ATP5G2
PLCH1
RPA4
ERCC3PARP1 PAX2
PINK1
ANKHOTUD7B
FDFT1NR1D1 EGR4
EPHB1
DHFRTRIM10 YME1L1
EXOSC1
BRAPOGT
ARHGEF15
GLI3 TK2ATP5BMDH2CASP1
NCOA3 RRM2
OAS3KIAA0368MAPK14
MTOR
SNAI2
NF1
ESR1
MTMR3
NR4A1
FOSB
TOX
ENTPD3
ME1GNAL
GPR124EDN1
PDE4D
LRRN3PDE4A
BGNGNAS
FBXO38CAMKMT
IMPAD1
LPHN3
ACE2
S1PR5RGS2
CCR9
CTSZ DPP4
SPINK5
RAB2ACAMTA1
SCARB1 HPR PRELP
KLF7UCN
GNAT1
ASPNHSPB6
PDE6DMAP4K4
LPL
CLUPDE5ANR1H4
PPP2R5B
MOCS1
PPP2R3A
GABRR1
SOWAHC
RNGTT
CES3
TFDP1
POLR2D
GNL3L
DDIT4
PKM
PTTG1
LRRFIP2SMC5
TTC9MSMO1 BTG2LRRFIP1
SIX5POLR3C
ATG10
KHSRP
MAP2K6
WWOX
POLR3GRSL1D1
HBS1L
GTF2H1FANCI
ATG16L1
NUAK1UBE2J1
PEX11B
ART3
TIMM17A
SMAD1
GATA3
ZBTB7A
TFDP1
QSOX1
ICAM1
Figure 3: �e protein-protein interaction (PPI) network of di�erentially expressed genes (DEGs). Red circles represent upregulated DEGs,and green diamonds represent downregulated DEGs.
Parkinson’s Disease 3
(version 1.50.0) [29] in R language, including backgroundcorrection, normalization, and expression calculation. An-notations to the probes were performed, and probes thatwere not matched to the gene symbol were excluded. )eaverage expression values were taken if different probesmapped to the same gene. DEGs in patients with PDcompared with those in healthy matched controls wereanalyzed using the limma package (version 3.10.3) [30] in Rlanguage. )e cutoff threshold was set to a p value of <0.05.
2.3. Pathway Enrichment Analysis. Gene ontology (GO)(http://www.geneontology.org/) analysis is commonly usedfor functional studies of large-scale genomic or tran-scriptomic data and classifies functions with respect to threeaspects: molecular function (MF), cellular component (CC),and biological process (BP) [31, 32].)e Kyoto Encyclopediaof Genes and Genomes (KEGG; http://www.kegg.jp/)pathway database [33] is widely used for systematic analysisof gene functions, linking genomic data with higher orderfunctional data. )e database for annotation, visualization,and integrated discovery (DAVID) is an integrated bi-ological knowledgebase with analytical tools used for sys-tematic and integrative analysis of large gene lists [34]. Inthis study, GO terms and KEGG pathway enrichment an-alyses for up- and downregulated DEGs were performedusing DAVID (version 6.8). )e cutoff thresholds were asfollows: an enrichment gene number count of ≥2 and a supergeometry inspection significance threshold p value of <0.05.
2.4. PPI Network Analysis. Search Tool for the Retrieval ofInteracting Genes/Proteins (STRING; http://www.string-db.org/) [35] is an online database that assesses and integratesPPIs. In this study, DEGs were mapped into the STRINGdatabase for PPI analysis, with a PPI score of 0.4 as theparameter setting.)e PPI network established by DEGs wasconstructed using the Cytoscape software (version 3.2.0)[36], and the topology scores of the nodes, including nodedegree in the PPI network, were analyzed using theCytoNCA plugin (version 2.1.6; http://apps.cytoscape.org/apps/cytonca) [37] (parameter setting: withoutweight). Degree was used for describing importance of
protein nodes in network. )e higher the degree was, themore important the nodes were in network. In addition,subnetworks were identified using the MCODE plugin [38]in the Cytoscape software, and subnetworks with a score of>5 were identified as key subnetworks. Finally, KEGGpathway enrichment analyses for the genes in the keysubnetworks were performed.
2.5. miRNA-Target Regulatory Network Analysis. )emiR2disease (http://www.mir2disease.org/) database[39] is a manually curated database that providesa comprehensive resource of miRNA deregulation invarious human diseases. miRWalk2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/) [40] is a com-prehensive database that presents predicted and validateddata, regarding miRNA targets in human, mouse, andrats. In this study, miRNAs related to PD were extractedfrom the miR2disease database, and experimentallyverified miRNA-gene regulatory pairs were obtained bysearching miRWalk2.0. Finally, a miRNA-target regula-tory network was constructed by comparing DEGs withobtained miRNA-gene regulatory pairs using the Cyto-scape software.
2.6. TF-Target Regulatory Network Analysis. )e genes in thePPI network described above were further analyzed to identifyTF-target interaction pairs that were then used to constructa TF-target regulatory network. )e iRegulon plugin (version1.3; http://apps.cytoscape.org/apps/iRegulon) [41] in theCytoscape software collects multiple human TF-target in-teraction databases such as Transfac, Jaspar, and Encode usingtwo computational methods: Motif and Track. In this study, weanalyzed the TF-target pairs using the iRegulon plugin andcompared them with TFs with DEGs in the PPI network,followed by a TF-target regulatory network construction. )eparameter settings were as follows: minimum identity betweenorthologous genes, 0.05 and maximum false discovery rate onmotif similarity, 0.001.)e normalized enrichment score (NES)indicates the reliability of the results, and the cutoff thresholdwas NES of >3.
Table 1: List of top 10 differentially expressed genes with higher degrees in protein-protein interaction network.
Gene Full name Description DegreeMAPK14 Mitogen-activated protein kinase 14 Down 68ESR1 Estrogen receptor 1 Up 54PTEN Phosphatase and tensin homolog Down 52MTOR Mechanistic target of rapamycin Up 40ATM ATM serine/threonine kinase Up 35ICAM1 Intercellular adhesion molecule 1 Down 33CD40 CD40 molecule Up 32AURKA Aurora kinase A Down 31PRKDC Protein kinase, DNA-activated, catalytic polypeptide Down 29TK2 )ymidine kinase 2, mitochondrial Up 29Degree was used for describing the importance of protein nodes in network. )e higher the degree was, the more important the nodes were in network.
4 Parkinson’s Disease
3. Results
3.1.Analysis ofDEGs. �e boxplot of the preprocessed dataindicated good normalization (Figure 1). In total, 22,277probes were obtained, among which 971 probes weredi�erentially expressed. After annotation, 819 DEGs inpatients with PD compared with those in healthy matchedcontrols were identi�ed (Supplementary Table 1), in-cluding 359 upregulated DEGs and 460 downregulatedDEGs.
3.2. Pathway Enrichment Analysis. GO and KEGG pathwayenrichment analyses for the up- and downregulated DEGswere performed (Supplementary Table 2). �e signi�cantGO terms and KEGG pathways are shown in Figure 2. �eupregulated DEGs were signi�cantly enriched in four KEGGpathways, namely, metabolic pathways, inositol phosphatemetabolism, mRNA surveillance pathway, and RNA deg-radation, and GO terms such as transcription, DNA-template processing, and rRNA processing (Figure 2(a)).
GPR18
CCR6
PTGER3
MCHR1
CCR9
NPY1R
CCR4
FPR3
S1PR5
(a)
NOP14
RSL1D1
DDX27
GNL3L
GLTSCR2
RTCA
PA2G4
(b)
OAS3
GNAT1
F2RICAM1
OASLHLA-C
GNAI2
RGS2SP100
CDC14A
RRM2
CCNA2
CDK3
AURKA
PLK3
CCNB1
TFDP1
PML
CASP1
MCM4
PARP1
CASP8
BRCA2
PRKDCVCAM1
CD40
RIPK2
(c)
Figure 4: Subnetworks of di�erentially expressed genes (DEGs). (a) Subnetwork a; (b) subnetwork b; (c) subnetwork c. Red circles representupregulated DEGs, and green diamonds represent downregulated DEGs.
Parkinson’s Disease 5
�e downregulated DEGs were enriched in pathways such asthose of in£uenza A, viral myocarditis, and TNF signalingand GO terms such as cytoplasm, cell surface, and interferongamma-mediated signaling pathway (Figure 2(b)).
3.3. PPI Network Analysis. �e PPI network, including 605nodes and 1937 PPI pairs, is shown in Figure 3. �e top 10DEGs with the highest degree included �ve upregulatedDEGs such as estrogen receptor 1 (ESR1), mechanistic targetof rapamycin (MTOR), ATM serine/threonine kinase(ATM), CD40 molecule (CD40) and thymidine kinase 2,mitochondrial (TK2), and �ve downregulated DEGs such asmitogen-activated protein kinase 14 (MAPK14), phosphatase
and tensin homolog (PTEN), intercellular adhesion molecule1 (ICAM1), aurora kinase A (AURKA), and protein kinase,DNA-activated, catalytic polypeptide (PRKDC) (Table 1).�ree subnetworks were identi�ed (subnetworks a–c). Sub-network a (Figure 4(a)) included nine nodes and 36 PPI pairs,and these genes were signi�cantly enriched in three KEGGpathways (Table 2), including neuroactive ligand-receptorinteraction, chemokine signaling pathway, and cytokine-cytokine receptor interaction. Subnetwork b (Figure 4(b))included seven nodes and 21 PPI pairs, and these geneswere not enriched in any KEGG pathway. Subnetwork c(Figure 4(c)) included 27 nodes and 81PPI pairs, and these geneswere enriched in 12 KEGG pathways (Table 2), such as cellcycle, herpes simplex infection, and NF-κB signaling pathways.
Table 2: List of KEGG pathways of subnetworks.
Subnetwork PathwayID Pathway name Count p value Genes
Subnetworka
hsa04080 Neuroactive ligand-receptor interaction 5 1.40E−04 MCHR1, PTGER3, S1PR5, FPR3, NPY1Rhsa04062 Chemokine signaling pathway 3 1.80E−02 CCR9, CCR6, CCR4hsa04060 Cytokine-cytokine receptor interaction 3 2.74E−02 CCR9, CCR6, CCR4
Subnetworkc
hsa04110 Cell cycle 6 1.31E−04 CCNB1, CDC14A, PRKDC, CCNA2, MCM4,TFDP1
hsa05416 Viral myocarditis 4 1.62E−03 ICAM1, CASP8, HLA-C, CD40hsa05168 Herpes simplex infection 5 6.03E−03 SP100, CASP8, OAS3, PML, HLA-Chsa04514 Cell adhesion molecules 4 1.70E−02 VCAM1, ICAM1, HLA-C, CD40hsa05144 Malaria 3 1.78E−02 VCAM1, ICAM1, CD40hsa04621 NOD-like receptor signaling pathway 3 2.00E−02 CASP8, RIPK2, CASP1hsa04115 p53 signaling pathway 3 2.93E−02 CCNB1, RRM2, CASP8hsa05164 In£uenza A 4 3.32E−02 ICAM1, OAS3, PML, CASP1
hsa04914 Progesterone-mediated oocytematuration 3 4.30E−02 CCNB1, GNAI2, CCNA2
hsa05169 Epstein–Barr virus infection 4 4.42E−02 ICAM1, HLA-C, CD40, CCNA2hsa05203 Viral carcinogenesis 4 4.60E−02 SP100, CASP8, HLA-C, CCNA2hsa04064 NF-kappa B signaling pathway 3 4.84E−02 VCAM1, ICAM1, CD40
KEGG, Kyoto Encyclopedia of Genes and Genomes.
hsa-miR-133b
PTPLAD1
EDN1
SERBP1
PKM
hsa-miR-433-3p
YIPF6
POLE3
BTG2
ACVR1B
APLP2
SULT1C2
ATP1B3
CBS
PDE4D
C1orf21
PARP11
NIPAL3
TMEM38B
FAM63B
PPP2R1B
ZNF264
PARP1
KPNA6
ACTN2
XIAP
RPRD2AGPAT1
NREP
TCL1B
hsa-miR-7-5p
TSN
EFHD2
EXOSC2
KIF5B
MFSD9
PA2G4
GPR135
PTPRK
STK38
ASXL1
SPATS2L
RNF114
Figure 5: MicroRNA- (miRNA-) target regulatory networks of di�erentially expressed genes (DEGs). Triangles represent miRNAs, redcircles represent upregulated DEGs, and green diamonds represent downregulated DEGs.
6 Parkinson’s Disease
In addition, ICAM1 was involved in six KEGG pathwaysof subnetwork c, such as viral myocarditis, cell adhesionmolecules (CAMs), and NF-κB signaling pathways (Table 2).�e detailed information existed in PPI network, and threesubnetworks are shown in Supplementary Table 3.
3.4. miRNA-Target Regulatory Network Analysis. Accordingto the data from the miR2disease database, six miRNAs wereidenti�ed to be associated with PD and 698 miRNA-genepairs were obtained by searching miRWalk2.0. A total of40 miRNA-target interaction pairs were obtained by com-paring miRNA-gene pairs with DEGs, and subsequently, the
miRNA-target regulatory network was constructed. �enetwork (Figure 5) contained 40 miRNA-target interactionpairs and 43 nodes (Supplementary Table 4), among whichthree miRNAs (hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b) were included.
3.5. TF-Target Regulatory Network Analysis. According theinformation of TF-target interaction databases such asTransfac, Jaspar, and Encode in the Cytoscape software,a total of 83 TFs were identi�ed from the PPI network,forming 5371 TF-gene pairs. Among the 83 TFs, six weredi�erentially expressed: three upregulated ones, that is, zinc
SLC7A7
FERMT2
PLCH1
ASS1
GPSM2
TAL1
CADM1ZBTB7A
EFHD2
DUSP2PARP11
KCNMA1
CIB2
NFKBIA
CBX4
OGT
CYLD
ADCK3TSPAN13
SYNJ2
NCOA1
LRRFIP2
KYNU
SYT11
FANCI
CMKLR1
MTMR3
PLSCR1
ICAM1
TSPAN31
KLF9ARRB2
AKAP13NR1D1
CD86
FKBP5
TNFAIP3
PTPRK
ARIH1
CD40
GFRA2
SLA
TNPO1
ITSN2
SEMA3C
SP2
DSPPPFIBP1SPTBN1
TCF3
HLF PTN
HLA-C
MAPK4
B3GALT2
PFAS
TTBK2
BRD3KLF7
IVNS1ABP
AHCYL1TNIP3GATA3
GTF2A1
BANK1FRK
BMP6
ST14
TLX2
WIPF2
SATB2
OTUD7B
TRPC5NOP14
NUAK1
NPAS3MSI1
RORB
KIF17
SYNCRIP
OVOL1PDE4D
FNDC3A
ESR1
LARGE
ENC1
SCN3A
PROX1
DHODH
PDE3A
LRRN3
PRKDCGALNT10
STK38
GREB1L
NOTCH2
HOXC4
CAMTA1MID1
ZNF362SMG7
CORO2B
SAP30
NPY1R
KDELR1H2AFY
BFSP1
MR1
NEK1
TRPM3
VCANDUSP6
TRAF3IP2
QSOX1
CCR6MLLT10
PPP2R3AGLI3
ACSBG1
DPP4RBM15B
CTBP2
SLC6A14DOCK10
SMAD1
MAST4
ANXA4GNAO1
PCNX
CBLB
LRP1
TRPC4
SPRY2
ERCC3RRM2
SART3
ATM
MCM4
SBNO1
ANKH
SERBP1HPSE
ZCWPW1
AMFR
CHAF1AATP5G2
CCR9EZH1
SSRP1
MYO6
BTG1
NR1H4 DHFR
MECOM
CA2
SCN8A
TFDP1
TPD52
TOX DDX6
ASXL1
ETV1
SORT1
SH3BP5
IL22RA1CD96
Figure 6:�e TF-target regulatory network of di�erentially expressed genes (DEGs). Blue boxed �gures represent TFs, red circles representupregulated genes, and green diamonds represent downregulated genes. TF, transcription factor.
Parkinson’s Disease 7
finger and BTB domain-containing 7A (ZBTB7A), ovo-liketranscriptional repressor 1 (OVOL1), and GATA-bindingprotein 3, and three downregulated ones, that is, tran-scription factor dp-1 (TFDP1), SMAD family member 1(SMAD1), and quiescin sulfhydryl oxidase 1 (QSOX1). )eTF-target regulatory network (Figure 6) was constructed andincluded 166 nodes and 288 interaction pairs (Supple-mentary Table 5). )e top 20 nodes with the highest degreeare listed in Table 3, including the six TFs described aboveand 14 other DEGs, such as ectodermal-neural cortex 1,fibronectin type III domain-containing 3A, and midline 1,which were coregulated by the six TFs.
4. Discussion
PD is the second most common age-related neurodegen-erative disease. However, the pathogenesis and genes in-volved in PD are not well known [42]. In this study, weperformed a comprehensive bioinformatics analysis of theblood gene expression profile using the GSE72267 dataset.)e results suggested that four key pathways (metabolicpathways, TNF signaling pathway, rRNA processing, andcytoplasm), the key gene ICAM1, three miRNAs (hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b), and six TFs(ZBTB7A, OVOL1, GATA3, TFDP1, SMAD1, and QSOX)might play important roles in PD development.
Our results revealed that the upregulated DEGs wereenriched in the KEGG pathway “metabolic pathways” and the
GO term “rRNA processing,” and the downregulated DEGswere enriched in the KEGG pathway “TNF signaling path-way” and the GO term “cytoplasm.” A previous study [43]demonstrated that some metabolic patterns were altered inpatients with advanced PD. Multiple metabolic pathways arealso involved in PD [44], which supports our study results.Cytoplasmic inclusions are a pathological hallmark of PD[45]. Lewy body pathology is involved [46, 47], and glialcytoplasmic inclusions are associated with Lewy bodies [48].)us, the GO term “cytoplasm” may play a role in PD.Furthermore, TNF receptor-associated protein is excludedfrom the nucleolus and is sequestered to the cytoplasm byTNF receptor-associated factor 6, thereby altering ribosomalRNA (rRNA) biogenesis [49]. )e TNF signaling pathway isalso involved in PD [50], and rRNA transcription is repressedin patients with PD [51]. )erefore, the GO term “rRNAprocessing” and the KEGG pathway “TNF signaling pathway”may play important roles in PD. Altogether, the metabolicpathways, TNF signaling pathway, rRNA processing, andcytoplasm are essentially involved in PD pathogenesis.
ICAM1 was among the top 10 DEGs in the PPI network.Moreover, ICAM1 gene was involved in six KEGG pathwaysfor subnetwork c. ICAM1 is involved in the adhesion andtransmigration of leukocytes across the endothelium,promoting brain inflammation and resulting in braindiseases [52]. T helper 17 cells can exert a neurotoxic effect inthe brain parenchyma of patients with PD by interacting withICAM1 and leukocyte function-associated antigen 1 [53]. In
Table 3: List of top 20 nodes with higher degree in transcription factor-target regulatory network.
Gene Full name Description DegreeTFDP1∗ Transcription factor Dp-1 Down 62ZBTB7A∗ Zinc finger and BTB domain-containing 7A Up 55OVOL1∗ Ovo-like transcriptional repressor 1 Up 46SMAD1∗ SMAD family member 1 Down 45QSOX1∗ Quiescin sulfhydryl oxidase 1 Down 44GATA3∗ GATA-binding protein 3 Up 38ENC1 Ectodermal-neural cortex 1 Down 6FNDC3A Fibronectin type III domain-containing 3A Up 6MID1 Midline 1 Down 6PDE4D Phosphodiesterase 4D Down 5ZNF362 Zinc finger protein 362 Up 5CBLB Cbl proto-oncogene B Down 4LARGE LARGE xylosyl- and glucuronyltransferase Up 4
TRPC4 Transient receptor potential cation channel subfamilyC member 4 Down 4
CTBP2 C-terminal binding protein 2 Up 4GLI3 GLI family zinc finger 3 Down 4SCN3A Sodium voltage-gated channel alpha subunit 3 Up 4
TAL1 TAL BHLH transcription factor 1, erythroiddifferentiation factor Down 4
LRRN3 Leucine rich repeat neuronal 3 Up 3
MAST4 Microtubule-associated serine/threonine kinasefamily member 4 Up 3
∗Transcription factor.
8 Parkinson’s Disease
addition, ICAM1 is involved in persistent inflammation inPD [54]. Our results from the KEGG pathway analysis forgenes in subnetworks revealed that ICAM1 might play rolesin viral myocarditis and CAMs and thus contributed to PD.
)e miRNA-target regulatory network analysis identifiedthree miRNAs involved in PD, namely, hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b. A study described miR-7-2dysregulation (the stem loop of hsa-miR-7-5p) in Parkinson’spatient’s leukocytes [55] and revealed that hsa-miR-7-5pexpression decreased in PD, possibly upregulating α-SYN,a PD-related gene [56].)e variation of the hsa-miR-433- (thestem loop of hsa-miR-433-3p-) binding site of fibroblastgrowth factor 20 can lead to α-SYN overexpression, in-creasing the risk for PD [57]. hsa-miR-133b expression isincreased in the cerebrospinal fluid of patients with PD[58]; however, its expression levels in serum is decreased,which is related to low serum ceruloplasmin levels [59].hsa-miR-133b is also deficient in the midbrain tissue ofpatients with PD and is associated with the maturation andfunction of midbrain dopaminergic neurons [60]. Notably,reduced circulating levels of miR-433 and miR-133b areconsidered as promising biomarkers for PD [61].)erefore,we speculate that the three miRNAs, including hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b may play impor-tant roles in PD.
TFs are important regulators of target gene expressions[53, 62]. In this study, we analyzed DEGs in the PPI networkto screen TFs involved in PD. Among the 83 TFs identifiedin the PPI network, six were found to be differentiallyexpressed. ZBTB7A, OVOL1, and GATA3 were upregulatedin patients with PD compared with those in healthy matchedcontrols, whereas TFDP1, SMAD1, and QSOX1 weredownregulated. ZBTB7A is a tumor suppressor, which isinvolved in several cancers such as prostate and nonsmallcell lung cancers [63–65]. OVOL1, encoding a zinc fingerprotein, is expressed in embryonic epidermal progenitorcells and is an inducer of mesenchymal-to-epithelial tran-sition in human cancers [66, 67]. GATA3, a member of theGATA family, is a regulator of T-cell development and playsroles in endothelial cells [68, 69]. TFDP1 is involved in thecell cycle and contributes to hepatocellular carcinomas[70, 71], SMAD1 is involved in multiple pathways [72, 73],andQSOX1 plays roles in some cancers such as breast cancerand neuroblastoma [74–76]. However, there are few reportsregarding the involvement of these TFs in PD. Hence,further studies regarding the associations between the TFsidentified in this study and PD are warranted.
In conclusion, our data demonstrated that the metabolicpathways, TNF signaling pathway, rRNA processing, andcytoplasm play important roles in PD pathogenesis; ICAM1might also play a vital role. Besides six TFs, three miRNAs,including hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b, may be involved in PD. However, because of thestudy limitations, further investigation remains to be per-formed in the future.
Conflicts of Interest
)e authors declare that there are no conflicts of interestregarding the publication of this article.
Acknowledgments
)is study was supported by the Construction of AccurateTechnology Innovation Centers of Nervous System Disease,Jilin Province (no. 20170623006TC), and Study on theMechanism of the Parkinson lncrna, Jilin Provincial De-partment of Finance Project.
Supplementary Materials
Supplementary 1. Table 1: all up- and downregulated dif-ferentially expressed genes.Supplementary 2. Table 2: GO and KEGG pathway en-richment analyses for the up- and downregulated differ-entially expressed genes. GO, Gene Ontology; KEGG, KyotoEncyclopedia of Genes and Genomes.Supplementary 3. Table 3: the detailed information existingin protein-protein interaction (PPI) network and threesubnetworks.Supplementary 4. Table 4: the detailed information about themiRNA-target regulatory network.Supplementary 5. Table 5: the detailed information abouttranscription factor- (TF-) target regulatory network.
References
[1] W. Dauer and S. Przedborski, “Parkinson’s disease: mecha-nisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003.
[2] A. E. Lang and A. M. Lozano, “Parkinson’s disease. Second oftwo parts,” New England Journal of Medicine, vol. 339, no. 16,pp. 1130–1143, 1998.
[3] A. E. Lang and A. M. Lozano, “Parkinson’s disease,” NewEngland Journal of Medicine, vol. 37, p. 198, 1998.
[4] L. V. Kalia and A. E. Lang, “Parkinson’s disease,” Lancet,vol. 386, no. 9996, pp. 896–912, 2015.
[5] D. J. Moore, A. B. West, V. L. Dawson, and T. M. Dawson,“Molecular pathophysiology of Parkinson’s disease,” AnnualReview of Neuroscience, vol. 28, no. 1, pp. 57–87, 2005.
[6] S. K. Bae, C. H. Heo, D. J. Choi et al., “A ratiometric two-photon fluorescent probe reveals reduction in mitochondrialH2S production in Parkinson’s disease gene knockout as-trocytes,” Journal of the American Chemical Society, vol. 135,no. 26, pp. 9915–9923, 2013.
[7] R. Calligaris, M. Banica, P. Roncaglia et al., “Blood tran-scriptomics of drug-naıve sporadic Parkinson’s disease pa-tients,” BMC Genomics, vol. 16, no. 1, pp. 1–14, 2015.
[8] L. Gong, Q. L. Zhang, N. Zhang et al., “Neuroprotection byurate on 6-OHDA-lesioned rat model of Parkinson’s disease:linking to Akt/GSK3β signaling pathway,” Journal of Neu-rochemistry, vol. 123, no. 5, pp. 876–885, 2012.
[9] K. U. Tufekci, E. C. Bayin, S. Genc, and K. Genc, “)eNrf2/ARE pathway: a promising target to counteract mito-chondrial dysfunction in Parkinson’s disease,” Parkinson’sDisease, vol. 2011, Article ID 314082, 14 pages, 2011.
Parkinson’s Disease 9
[10] D. Cheng, A. M. Jenner, G. Shui et al., “Lipid pathway al-terations in Parkinson’s disease primary visual cortex,” PLoSOne, vol. 6, Article ID e17299, 2011.
[11] R. Deumens, A. Blokland, and J. Prickaerts, “ModelingParkinson’s disease in rats: an evaluation of 6-OHDA lesionsof the nigrostriatal pathway,” Experimental Neurology,vol. 175, no. 2, pp. 303–317, 2002.
[12] E. Leroy, R. Boyer, G. Auburger et al., “)e ubiquitin pathwayin Parkinson’s disease,” Nature, vol. 395, no. 6701,pp. 451-452, 1998.
[13] T. Pan, S. Kondo, W. Le, and J. Jankovic, “)e role ofautophagy-lysosome pathway in neurodegeneration associ-ated with Parkinson’s disease,” Brain, vol. 131, no. 8,pp. 1969–1978, 2008.
[14] R. M. Perrett, Z. Alexopoulou, and G. K. Tofaris, “)eendosomal pathway in Parkinson’s disease,” Molecular &Cellular Neurosciences, vol. 66, pp. 21–28, 2015.
[15] A. L. Whone, R. Y. Moore, P. P. Piccini, and D. J. Brooks,“Plasticity of the nigropallidal pathway in Parkinson’s dis-ease,” Annals of Neurology, vol. 53, no. 2, pp. 206–213, 2003.
[16] B. D. Cholewa, X. Liu, and N. Ahmad, “)e role of polo-likekinase 1 in carcinogenesis: cause or consequence?,” CancerResearch, vol. 73, no. 23, pp. 6848–6855, 2013.
[17] E. Miñonesmoyano, S. Porta, G. Escaramıs et al., “MicroRNAprofiling of Parkinson’s disease brains identifies earlydownregulation of miR-34b/c which modulate mitochondrialfunction,” Human Molecular Genetics, vol. 20, no. 15, p. 3067,2011.
[18] M. L. De, E. Coto, L. F. Cardo et al., “Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson’s disease,” AmericanJournal of Medical Genetics Part B Neuropsychiatric genetics:Be Official Publication of the International Society of Psy-chiatric Genetics, vol. 153B, no. 6, pp. 1234–1239, 2010.
[19] S. Li, X. Lv, K. Zhai et al., “MicroRNA-7 inhibits neuronalapoptosis in a cellular Parkinson’s disease model by targetingBax and Sirt2,” American Journal of Translational Research,vol. 8, no. 2, pp. 993–1004, 2016.
[20] Y. Zhou, M. Lu, R. H. Du et al., “MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuro-inflammation in the pathogenesis of Parkinson’s disease,”Molecular Neurodegeneration, vol. 11, no. 1, p. 28, 2016.
[21] W. Le, D. Nguyen, X. W. Lin et al., “Transcription factorPITX3 gene in Parkinson’s disease,” Neurobiology of Aging,vol. 32, no. 4, pp. 750–753, 2011.
[22] J. Li, J. A. Dani, and W. Le, “)e role of transcription factorPitx3 in dopamine neuron development and Parkinson’sdisease,” Current Topics in Medicinal Chemistry, vol. 9, no. 10,pp. 855–859, 2009.
[23] X. Xie, H. Liu, and Y. Gao, “Expression changes of tran-scription factor EN1 in the midbrain of mice model ofParkinson’s disease,” Chinese Journal of RehabilitationMedicine, vol. 27, pp. 197–200, 2012.
[24] A. Cuadrado, P. Morenomurciano, and J. Pedrazachaverri,“)e transcription factor Nrf2 as a new therapeutic target inParkinson’s disease,” Expert Opinion on Berapeutic Targets,vol. 13, no. 3, pp. 319–329, 2009.
[25] P. M. Flood, L. Qian, L. J. Peterson et al., “Transcriptionalfactor NF-κB as a target for therapy in Parkinson’s disease,”Parkinson’s Disease, vol. 2011, Article ID 216298, 8 pages, 2011.
[26] M. Kurzawski, M. Białecka, J. Sławek, G. Kłodowskaduda, andM. Drozdzik, “Association study of GATA-2 transcriptionfactor gene (GATA2) polymorphism and Parkinson’s dis-ease,” Parkinsonism & Related Disorders, vol. 16, no. 4,pp. 284–287, 2009.
[27] N. V. Soshnikova, N. E. Vorob’Eva, A. A. Kolacheva et al.,“Ratio of transcription factor PHF10 splice variantsin lymphocytes as a molecular marker of Parkinson’s disease,”Molecular Biology, vol. 50, no. 4, pp. 695–702, 2016.
[28] T. Barrett, T. O. Suzek, D. B. Troup et al., “NCBI GEO: miningmillions of expression profiles—database and tools,” NucleicAcids Research, vol. 33, pp. D562–D566, 2005.
[29] L. Gautier, L. Cope, B. M. Bolstad, and R. A. Irizarry,“affy—analysis of Affymetrix GeneChip data at the probelevel,” Bioinformatics, vol. 20, no. 3, pp. 307–315, 2004.
[30] G. Smyth and G. K. Smyth, “Limma: linear models formicroarray data,” Bioinformatics and Computational BiologySolution Using R and Bioconductor, Springer, Berlin,Germany, 2005.
[31] I. Hulsegge, A. Kommadath, and M. A. Smits, “Globaltest andGOEAST: two different approaches for Gene Ontologyanalysis,” BMC Proceedings, vol. 3, no. 4, p. S10, 2009.
[32] T. G. O. Consortium, M. Ashburner, C. A. Ball et al., “Geneontology: tool for the unification of biology,” Nature Genetics,vol. 25, no. 1, pp. 25–29, 2000.
[33] M. Kanehisa and S. Goto, “KEGG: Kyoto Encyclopedia ofGenes and Genomes,” Nucleic Acids Research, vol. 27, no. 1,pp. 27–30, 1999.
[34] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematicand integrative analysis of large gene lists using DAVIDbioinformatics resources,” Nature Protocol, vol. 4, no. 1,pp. 44–57, 2009.
[35] D. Szklarczyk, A. Franceschini, S. Wyder et al., “STRING v10:protein-protein interaction networks, integrated over the treeof life,” Nucleic Acids Research, vol. 43, pp. D1–D447, 2015.
[36] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a softwareenvironment for integrated models of biomolecular in-teraction networks,” Genome Research, vol. 13, no. 11,pp. 2498–2504, 2003.
[37] Y. Tang, M. Li, J. Wang, Y. Pan, and F. X. Wu, “CytoNCA:a cytoscape plugin for centrality analysis and evaluation ofprotein interaction networks,” Bio Systems, vol. 127, pp. 67–72, 2014.
[38] W. P. Bandettini, P. Kellman, C. Mancini et al., “Multi-Contrast Delayed Enhancement (MCODE) improves de-tection of subendocardial myocardial infarction by lategadolinium enhancement cardiovascular magnetic resonance:a clinical validation study,” Journal of Cardiovascular Mag-netic Resonance, vol. 14, no. 1, p. 83, 2012.
[39] Q. Jiang, Y. Wang, Y. Hao et al., “miR2Disease: a manuallycurated database for microRNA deregulation in humandisease,” Nucleic Acids Research, vol. 37, pp. D98–104, 2009.
[40] H. Dweep and N. Gretz, “miRWalk2.0: a comprehensive atlasof microRNA-target interactions,” Nature Methods, vol. 12,no. 8, p. 697, 2015.
[41] R. Janky, A. Verfaillie, H. Imrichova et al., “iRegulon: froma gene list to a gene regulatory network using large motif andtrack collections,” Plos Computational Biology, vol. 10, no. 7,p. e1003731, 2014.
[42] Y. Feng, J. Jankovic, and Y. C.Wu, “Epigenetic mechanisms inParkinson’s disease,” Journal of the Neurological Sciences,vol. 349, no. 1-2, pp. 3–9, 2015.
[43] M. G. Moreno, C. Sanchez, G. Vazquez, J. Altamirano, andM. Avilarodriguez, “Metabolic mismatch patterns in patientswith advanced Parkinson’s disease on 18F-FDOPA, 11C-Raclopride and 11C-DTBZ PET/CT,” Journal of NuclearMedicine, vol. 56, no. 3, p. 1890, 2015.
[44] M. Bonin, S. Poths, H. Osaka, YL. Wang, K. Wada, andO. Riess, “Microarray expression analysis of gad mice
10 Parkinson’s Disease
implicates involvement of Parkinson’s disease associatedUCH-L1 in multiple metabolic pathways,” Molecular BrainResearch, vol. 126, no. 1, pp. 88–97, 2004.
[45] M. Ihara, H. Tomimoto, H. Kitayama et al., “Association of thecytoskeletal GTP-binding protein Sept4/H5 with cytoplasmicinclusions found in Parkinson’s disease and other synuclei-nopathies,” Journal of Biological Chemistry, vol. 278, no. 26,pp. 24095–24102, 2003.
[46] K. A. Mills, Z. Mari, C. Bakker et al., “Gait function and locuscoeruleus Lewy body pathology in 51 Parkinson’s diseasepatients,” Parkinsonism & Related Disorders, vol. 33,pp. 102–106, 2016.
[47] Y. Saito, A. Shioya, T. Sano, H. Sumikura, M. Murata, andS. Murayama, “Lewy body pathology involves the olfactorycells in Parkinson’s disease and related disorders,” MovementDisorders Official Journal of the Movement Disorder Society,vol. 31, no. 1, pp. 135–138, 2016.
[48] A. Mochizuki, Y. Komatsuzaki, and S. I. Shoji, “Association ofLewy bodies and glial cytoplasmic inclusions in the brain ofParkinson’s disease,” Acta Neuropathologica, vol. 104,pp. 534–537, 2002.
[49] S. Vilotti, M. Codrich, M. D. Ferro et al., “Parkinson’s diseaseDJ-1 L166P alters rRNA biogenesis by exclusion of TTRAPfrom the nucleolus and sequestration into cytoplasmic ag-gregates via TRAF6,” PLoS One, vol. 7, no. 4, Article IDe35051, 2012.
[50] T. N. Martinez, “Neuroinflammation, TNF, and ceramidesignaling: putative pathways for neurotoxicity in Parkinson’sdisease,” Diss., 2010.
[51] H. Kang and J. H. Shin, “Repression of rRNA transcription byPARIS contributes to Parkinson’s disease,” Neurobiology ofDisease, vol. 73, pp. 220–228, 2015.
[52] J. Y. Choi and S. A. Jo, “KDM7A histone demethylase me-diates TNF-α-induced ICAM1 protein upregulation bymodulating lysosomal activity,” Biochemical & BiophysicalResearch Communications, vol. 478, no. 3, pp. 1355–1362,2016.
[53] Q. Zhao, H. Liu, C. Yao, J. Shuai, and X. Sun, “Effect ofdynamic interaction between microRNA and transcriptionfactor on gene expression,” Biomed Research International,vol. 2016, Article ID 2676282, 10 pages, 2016.
[54] J. Miklossy, D. D. Doudet, C. Schwab, S. Yu, E. G. Mcgeer, andP. L. Mcgeer, “Role of ICAM-1 in persisting inflammation inParkinson disease and MPTP monkeys,” Experimental Neu-rology, vol. 197, no. 2, pp. 275–283, 2006.
[55] L. Soreq, M. Bronstein, D. S. Greenberg et al., “Small RNAsequencing-microarray analyses in Parkinson leukocytes re-veal deep brain stimulation-induced splicing changes thatclassify brain region transcriptomes,” Frontiers in MolecularNeuroscience, vol. 6, p. 10, 2013.
[56] E. Junn, K. W. Lee, B. S. Jeong, T. W. Chan, J. Y. Im, andM. M. Mouradian, “Repression of alpha-synuclein expressionand toxicity by microRNA-7,” Proceedings of the NationalAcademy of Sciences of the United States of America, vol. 106,no. 31, pp. 13052–13507, 2009.
[57] G. Wang, J. van der Walt, Y. Li et al., “Variation in themiRNA-433 binding site of FGF20 confers risk for Parkinsondisease by overexpression of alpha-synuclein,” AmericanJournal of Human Genetics, vol. 82, no. 2, pp. 283–289, 2008.
[58] X. Ma, J. Ren, Y. Jiao, J. Yang, F. Xu, and Y. Song, “Expressionof miR-133b and its clinical significance in cerebrospinal fluidof patients with Parkinson’s disease,” Modern Journal of In-tegrated Traditional Chinese & Western Medicine, vol. 23,no. 24, pp. 2656–2658, 2014.
[59] N. Zhao, L. Jin, G. Fei, Z. Zheng, and C. Zhong, “SerummicroRNA-133b is associated with low ceruloplasmin levels inParkinson’s disease,” Parkinsonism & Related Disorders,vol. 20, no. 11, pp. 1177–1180, 2014.
[60] J. Kim, K. Inoue, J. Ishii et al., “A MicroRNA feedback circuitin midbrain dopamine neurons,” Science, vol. 317, no. 5842,pp. 1220–1224, 2007.
[61] X. Zhang, R. Yang, B. L. Hu et al., “Reduced circulating levelsof miR-433 and miR-133b are potential biomarkers forParkinson’s disease,” Frontiers in Cellular Neuroscience,vol. 11, p. 170, 2017.
[62] N. J. Martinez and A. J. Walhout, “)e interplay betweentranscription factors and microRNAs in genome-scale reg-ulatory networks,” Bioessays, vol. 31, no. 4, pp. 435–445, 2009.
[63] K. Apostolopoulou, I. S. Pateras, K. Evangelou et al., “Geneamplification is a relatively frequent event leading to ZBTB7A(Pokemon) overexpression in non-small cell lung cancer,”Journal of Pathology, vol. 213, no. 3, pp. 294–302, 2007.
[64] X. S. Liu, J. E. Haines, E. K. Mehanna et al., “ZBTB7A acts asa tumor suppressor through the transcriptional repression ofglycolysis,” Genes & Development, vol. 28, no. 17, pp. 1917–1928, 2014.
[65] G. Wang, A. Lunardi, J. Zhang et al., “Zbtb7a suppressesprostate cancer through repression of a Sox9-dependentpathway for cellular senescence bypass and tumor in-vasion,” Nature Genetics, vol. 45, no. 7, pp. 739–746, 2013.
[66] M. Nair, A. Teng, V. Bilanchone, A. Agrawal, B. Li, and X. Dai,“Ovol1 regulates the growth arrest of embryonic epidermalprogenitor cells and represses c-myc transcription,” Journal ofCell Biology, vol. 173, no. 2, pp. 253–264, 2006.
[67] H. Roca, J. Hernandez, S. Weidner et al., “Transcriptionfactors OVOL1 and OVOL2 induce the mesenchymal toepithelial transition in human cancer,” PLoS One, vol. 8,no. 10, Article ID e76773, 2013.
[68] I. C. Ho, T. S. Tai, and S. Y. Pai, “GATA3 and the T-celllineage: essential functions before and after T-helper-2-celldifferentiation,” Nature Reviews Immunology, vol. 9, no. 2,pp. 125–135, 2009.
[69] H. Song, J. Suehiro, Y. Kanki et al., “Critical role for GATA3 inmediating Tie2 expression and function in large vessel en-dothelial cells,” Journal of Biological Chemistry, vol. 284,no. 42, pp. 29109–29124, 2009.
[70] X. Lu, X. D. Lv, Y. H. Ren et al., “Dysregulation of TFDP1 andof the cell cycle pathway in high-grade glioblastoma multi-forme: a bioinformatic analysis,” Genetics & Molecular Re-search, vol. 15, no. 2, 2016.
[71] K. Yasui, H. Okamoto, S. Arii, and J. Inazawa, “Association ofover-expressed TFDP1 with progression of hepatocellularcarcinomas,” Journal of Human Genetics, vol. 48, no. 12,pp. 609–613, 2003.
[72] LC. Fuentealba, E. Eivers, A. Ikeda et al., “Integrating pat-terning signals: Wnt/GSK3 regulates the duration of theBMP/Smad1 signal,” Cell, vol. 131, no. 5, pp. 980–993, 2007.
[73] M. MacıAssilva, P. A. Hoodless, S. J. Tang, M. Buchwald, andJ. L. Wrana, “Specific activation of Smad1 signaling pathwaysby the BMP7 type I receptor, ALK2,” Journal of BiologicalChemistry, vol. 273, no. 40, pp. 25628–25636, 1998.
[74] D. Araujo and L. Nakao, “Expression level of quiescin sulf-hydryl oxidase 1 (QSOX1) in neuroblastomas,” EuropeanJournal of Histochemistry, vol. 58, no. 1, p. 2228, 2014.
[75] D. F. Lake and D. O. Faigel, “)e emerging role of QSOX1 incancer,” Antioxid Redox Signal, vol. 21, no. 3, pp. 485–496,2014.
Parkinson’s Disease 11
[76] N. Pernodet, F. Hermetet, P. Adami et al., “High expression ofQSOX1 reduces tumorogenesis, and is associated with a betteroutcome for breast cancer patients,” Breast Cancer Research,vol. 14, no. 5, p. R136, 2012.
12 Parkinson’s Disease
Stem Cells International
Hindawiwww.hindawi.com Volume 2018
Hindawiwww.hindawi.com Volume 2018
MEDIATORSINFLAMMATION
of
EndocrinologyInternational Journal of
Hindawiwww.hindawi.com Volume 2018
Hindawiwww.hindawi.com Volume 2018
Disease Markers
Hindawiwww.hindawi.com Volume 2018
BioMed Research International
OncologyJournal of
Hindawiwww.hindawi.com Volume 2013
Hindawiwww.hindawi.com Volume 2018
Oxidative Medicine and Cellular Longevity
Hindawiwww.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation http://www.hindawi.com Volume 2013Hindawiwww.hindawi.com
The Scientific World Journal
Volume 2018
Immunology ResearchHindawiwww.hindawi.com Volume 2018
Journal of
ObesityJournal of
Hindawiwww.hindawi.com Volume 2018
Hindawiwww.hindawi.com Volume 2018
Computational and Mathematical Methods in Medicine
Hindawiwww.hindawi.com Volume 2018
Behavioural Neurology
OphthalmologyJournal of
Hindawiwww.hindawi.com Volume 2018
Diabetes ResearchJournal of
Hindawiwww.hindawi.com Volume 2018
Hindawiwww.hindawi.com Volume 2018
Research and TreatmentAIDS
Hindawiwww.hindawi.com Volume 2018
Gastroenterology Research and Practice
Hindawiwww.hindawi.com Volume 2018
Parkinson’s Disease
Evidence-Based Complementary andAlternative Medicine
Volume 2018Hindawiwww.hindawi.com
Submit your manuscripts atwww.hindawi.com